Keywords
Immunosuppression therapy
Vaccines
Epidemiologic profile
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the indication and administration of vaccines in post-Bone Marrow Transplant (HSCT) patients according to the CRIE calendar, the epidemiological profile, transplantation, complete or incomplete vaccination, and factors associated with non-vaccination of adult and pediatric post-HSCT patients. Methods: Observational non-concurrent cohort study, carried out through evaluation of medical records in a reference service from 2012 to 2021. Data were collected on age and sex, type of transplant, disease that led to the transplant, immunosuppression, immunoglobulin, presence of acute or chronic GVHD, indication of administered vaccines and doses, contraindications, and reasons for non-vaccination. Results: The main finding was the lack of vaccination records, with 64% of adults (110) and 61.2% of children (104) without records at 6 months. Conclusion: The indication and application of post-HSCT vaccines according to the CRIE calendar are not adequate in the institution. It is recommended that the team be trained and that a specialized nurse and a transplant doctor or infectious disease specialist be included to organize vaccination control through cards, phone calls or text messages, in addition to notifying patients of the reasons for not being vaccinated.
References
ARIZA-HEREDIA EJ, et al. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014; 16(6): 878-886.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunização e Doenças Transmissíveis. Manual dos Centros de Referência para Imunobiológicos Especiais [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação- Geral do Programa Nacional de Imunizações. Brasília: Ministério da Saúde, 2019; 5.
CARPENTER PA e ENGLUND JA. How I vaccinate blood and marrow transplant recipients. Blood Adv, 2016; 127(23): 2824-2832.
CONRAD, A. et al. Efficacy and safety of revaccination against tetanus, diphtheria, Haemophilus influenzae type b and hepatitis B virus in a prospective cohort of adult recipients of allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 2020; 26(9): 1729–1737.
FUNKE M, et al. VI Consensus of the Brazilian Society of Bone Marrow Transplantation (SBTMO) - Consensus on Graft-versus-Host Disease (GVHD). JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2023; 4(1): 188–188.
HILGENDORF I, et al. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine, 2011; 29(16): 2825-33.
HUDSPETH MP, et al. Post-hematopoietic stem cell transplant immunization practices in the Pediatric Blood and Marrow Transplant Consortium. Pediatr Blood Cancer, 2010, 54(7): 970-975.
JANSSEN M, et al. Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review. Cancers, 2021; 13(23): 6140.
LEE DG. Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea. Infect Chemother, 2013; 45(3): 272-282.
LJUNGMAN P, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant, 2009; 44(8): 521-526.
LJUNGMAN P, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplantation, 2005; 35(8): 737–746.
MACHADO CM, et al. Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil. 2002; 99(1): 83–87.
MACHADO CM. Reimmunization after hematopoietic stem cell transplantation. Expert Rev Vaccines. 2005; 4(2): 219-28.
MAJEED A, et al. Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. Biol Blood Marrow Transplant, 2020; 26(2): 38-50.
MIKULSKA M, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases, 2019; 19(6): 188–199.
MILLER PDE, et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). J Infect, 2023; 86(1): 1-8.
SABAINI PMS e MACHADO, et al. Use of live viral vaccines after HCT: Still a lot to learn. Transpl Infect Dis. 2023; 25(2): 14044.
SAHIN U, et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother, 2016, 22(8): 505-514.
SBIM. Calendários de Vacinação pacientes especiais. 2021-2022. Disponível em: https ://sbim.org.br/calendarios-de-vacinacao. Acessado em: 14 de setembro de 2023.
SBIM. Pacientes de risco: o conhecimento da população sobre os CRIE e o calendário de vacinação. 2020. Disponível em: https ://sbim.org.br/acoes/campanhas-apoio/1344-campanha-crie-mais-protecao. Acessado em: 14 de setembro de 2023.
SILVA PM, et al. Difficulties in the revaccination program of hematopoietic stem cell transplantation recipients. Rev Inst Med Trop São Paulo. 2017; 59: 69.
TESTA LHA, et al. Compliance with yellow fever and measles vaccines in the revaccination program post-hematopoietic cell transplantation. Transpl Infect Dis. 2023; 14098.
WIEDUWILT MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv, 2022; 6(1): 339–357.